Moleculin Completes Dosing in Part A of Pivotal Annamycin Trial for AML

Bitget2026/10/30 12:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moleculin Biotech completed Part A dosing in its pivotal Phase 2/3 MIRACLE trial for adults with relapsed or refractory acute myeloid leukemia.
The trial evaluates Annamycin combined with cytarabine, with comprehensive Part A results expected in the first quarter of 2027.
The findings will guide Annamycin dose selection for Part B across patients whose leukemia resisted or returned following prior treatment.
Blinded interim data continued to show no heart toxicity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300840PRIMZONEFULLFEED9856644) on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moleculin Completes Dosing in Part A of Pivotal Annamycin Trial for AML

You may also like

Crypto prices